Anne Wojcicki, CoFounder 23andMe, helps us access, understand & benefit from our DNA

Anne Wojcicki
1 follower
1 Video View·Apr 9, 2026
It's another awesome interview from the Rock Health CEO Summit, with Jason sitting down with Anne Wojcicki, CoFounder of 23andMe. 23andMe helps people access, understand, and benefit from the human genome by giving us our own DNA information, which in turn can be used to help prevent disease. They have been working on this for nearly 10 years by offering saliva-based genetics test kits for $99 directly to consumers. Jason and Anne discuss 23andMe’s business, customer success stories from sequencing DNA, how FDA regulation has impacted the company (and all healthcare startups), what the future of healthcare should look like, how big of an opportunity healthcare is for startups, security of healthcare data, and much more.
Today's episode of This Week in Startups is brought to you by InVision.
Find out why so many hot startups are using InVision to prototype,
present, and collaborate on design in real time.
Sign up for a 90-day free trial today at InVisionApp.com slash twist.
And by Citrix GoToMeeting.
Meeting is believing.
Visit GoToMeeting.com and click on the try it free button and sign up for a 30-day free trial.
In this episode, Jason sits down with Anne Mojecki,
co-founder of personal genomics and biotechnology company 23andMe at the Rock Health Summit.
Anne Mojecki is the founder of 23andMe.
Co-founder.
Co-founder, yes.
Oh, that's always a very important thing to get right.
Many apologies.
Nine years you've been at it now?
Getting close to 10, huh?
A long time.
It's a long time.
Does it feel like a long time?
I mean, I can't really remember the life without it, yeah.
No, but it doesn't feel that...
I mean, it goes quickly.
Yeah.
So describe for everybody what's the state of the business today in terms of the scale of it?
Because it's moved pretty quickly and you've been at it for a long time.
How many people have taken a kit and actually done it?
And how many people work at the company now?
So we met Yuri Milner about two years ago.
And I sat down with him and I said, you know,
he was really interested in healthcare and transforming things.
And I said, you know, my dream would be like,
you could really change the whole healthcare system
if you get a million people in the database.
And he's like, well, what do you need to get to a million?
And I said, I just need cash.
And he's like, okay, like literally the next day...
He has that.
And so the next week we got money.
And two weeks later, we dropped the price to $99
with an initiative to get a million people in the database.
And it's kind of fun because it shows like we can move that quickly on things.
And it was the hypothesis at the time that if you had massive numbers of people,
would there be sort of this business model around the data?
And clearly at $99, there's not much of a margin on that.
If any.
I'm wondering, like, what does it actually cost to do this?
It's, I mean, the problem is you get scale with volume.
And especially on the services.
So again, it's roughly, you can assume it's sort of a breakeven.
Yeah.
But the hypothesis that we had really panned out where
even though we got the FDA warning letter,
so we had to stop returning health information.
We have 850,000 people today.
And we have, I think, sort of achieved this critical mass
where there's enough people around the country who have the information
that it starts to go viral.
But also it's attracted the attention of the research world.
We're starting to do really big collaborations.
Like we announced a big project that we're doing with Genentech
where we're getting real dollars in.
And we have 12 other partnerships with pharma companies,
31 academic partnerships.
So we're starting to see this massive interest in the database that we have built.
And we did an event at the American Society of Human Genetics.
And we planned for 150, 200 people to come.
And 700 people later in the fire marshals, et cetera,
we had to sort of tame it.
There was so much enthusiasm about the ability that we're trying to
enable access broadly to the research database.
So what's interesting there, and the reason why I wanted to tell the story,
especially with this crowd, is in part, as an entrepreneur, you make a bet.
We made a bet that a million people would be transformative.
And that hypothesis is playing out.
It really does make a big difference.
From a company-wide, we have roughly 180 people in the company now.
And we are growing pretty rapidly.
So you spent $100 million building this database, essentially.
Something in that ballpark.
I'd say some of that went to the FDA.
Some of that went to the FDA, yes.
You got a fine of some type.
So that issue...
We didn't get a fine, but regulation costs money.
And part of it, as you can imagine, when we actually relaunch a product,
then I can say for sure that we cannot make money at $99 because regulation is expensive.
Yeah.
And so the thing the FDA was upset about was you were actually telling consumers
what some of these markers might mean for them.
And to the just layperson, this seems crazy that I can't have information about my own
possible future.
What's the issue?
A doctor needs to deliver that to me who doesn't even understand what you do?
Is that what they want to have happen?
You send it to a doctor, then the doctor tells me what you know better than any doctor could
ever know because you have a million people in the database?
Well, if you think about it, there's a lot of aspects of healthcare.
I wear contact lenses.
Why do I have to go...
My prescription doesn't change.
I have to go every year to get a new prescription.
So there's a lot of aspects of healthcare that still have this sort of white coat,
paternalistic mentality.
What happened for us is that there is a transition going in all of diagnostics and that right now,
majority of diagnostics and majority of labs are regulated by Medicare under CLIA.
And in part because the CLIA definition is vague enough that it's a controversial...
Like people argue all the time in the company about what is the definition
of a laboratory-developed test and do we fit that definition or not.
But clearly the FDA came after saying you are a medical device, not a laboratory-developed test.
You need to file as a medical device.
And the challenge there...
And this happened in 2010 when they said like, look, we're going to regulate this
direct-to-consumer space because we see direct-to-consumer as a higher risk.
And so there is...
You can argue there's this paternalism where we're saying because it's direct-to-consumer
that it has to be under this sort of stricter guidelines.
The challenge is that under CLIA, it's a little bit of a wild wet.
It's sort of a self-certification process.
And we are fitting into a infrastructure that works like your pacemakers.
And so there is the same kind of sort of rigor that we're going through that a pacemaker.
Okay.
I'm not an expert.
But information on a piece of paper about what possibly could happen to me in the future
in terms of diseases seems like a lot less dangerous than a pacemaker, you know, messing up.
You and I are...
Yeah.
I mean, we clearly...
It's a little confounding.
We didn't go...
I mean, we originally went to the FDA when we launched and they said we were not going
to be regulating you.
So, yeah.
I mean, I think part of the problem today is that there's not an informatics arm of the FDA.
And I look at lots of companies and that's what's interesting actually even here is I
meet lots of people now who, you know, like Max Levkin was talking about GLOW and that
they actually have these abilities to predict fertility problems, but that they're worried
about, you know, are they going to get into regulatory issues?
So I think that there's a real issue here of what is it that you can actually say from
sort of big data insights?
And what is it that you can say about data?
And I think that it becomes a little bit of an issue because you can get your genome today
and get your raw data from 23andMe and you can go anywhere in the world and have anybody
interpret it.
Or you yourself, you could just use our lookup tables and you could look at like, well, what's
the BRCA variants and what you got?
And you put those together.
So if I look it up, no problem.
But if you send it to me in a piece of paper, conveniently problem.
Correct.
So, and that's where there is...
And this is where I think there's a lot of discussion happening about how is it that
broadly informatics needs to be regulated.
Yeah, it does seem like this is new territory and maybe...
And I think it's an issue too, because the whole genome is coming out and it's going
to be cheap.
And so I don't fault the FDA for this idea.
Like, you want to make sure, you want to have some kinds of standards that are out there.
I'm not sure that, I mean, to the main point, I'm not sure that the medical device regulatory
path makes sense, but there should be standards of sorts.
And so you should know if I'm getting my cystic fibrosis results, like that there's been some
level of accuracy testing so that you know that you're getting that.
But is the current process as it's, you know, we've been working for one submission, one
single mutation in the million for the last year and change.
So we can't do that for a million SNPs.
Right.
Ah, yes.
InVision app is my favorite program right now, because design wins.
I was literally at a meeting and it was supposed to be like a 20 minute meeting at, beep, company,
I can't say.
And they were very interested in buying a company that I work with called, beep, I can't say.
And you know what I did?
I didn't even take out my phone to show them the product.
I opened InVision and I showed them, here's version two, here's version three, here's
secret project X, your secret project Y, your secret project Z.
And you know what they said?
This is amazing.
We very much would like to acquire this company.
I said, you want to acquire, beep, and you're telling me your company, beep, wants to acquire,
beep.
And I'm just like, this is going to be the greatest thing ever.
When this acquisition news comes out, people are going to go crazy all because I showed
them the gorgeous roadmap in InVision.
And I started clicking through it.
And then they said, can I see this?
And I said, of course you can see it.
And I went in and I said, share.
And I put in blank name at beep.com.
And they got the link on their phone.
They added it to their home screen.
And now they were looking it out on their phone.
They were looking at the new version of beep on their phone.
You want to close the deal?
You want to do it the way J-Cal does it?
I'm talking about myself in the third person like Kanye.
Pardon me, but I'm feeling pretty high on myself right now.
You want to do it like Kanye and J-Cal does it?
You just take out InVision.
You make a beautiful app mock-up and you send it.
And you're a baller because then they can look at your product and be like, damn, Kanye
makes great product.
J-Cal made great products.
Now, I just want to let you know, Kanye did not give me permission to endorse this product,
but J-Cal has 100%.
I guarantee you, Kanye is using this.
There's no way Kanye is not down with InVision because that is so hot.
I love it.
Twitter, Airbnb, Evernote, Adobe, and Kanye.
I've made the last part up.
I don't know if Kanye is using it or not.
He should be.
The best companies in the world do it.
InVision is giving away their starter plan for free for 90 days if you go to InVision.com
slash app.
Sorry, InVision dot app.
I got to get this link right.
InVision app.com slash twist.
I want you to go there right now.
InVision app.com slash twist.
And if you want me to invest in your company and your product's not built yet, do not send
me a business plan.
Because any monkey can make a business plan.
Business plan.
Fill it out with a bunch of nutty, crazy ideas.
Excel spreadsheet.
Put in a bunch of numbers.
I don't care.
You send me an InVision link.
Ooh, and I click it.
Ooh, and I see something beautiful.
Ooh, and I do it on the phone while I'm walking down Market Street on my way to go to the
battery and get my workout on.
Ooh, I'm on the treadmill.
I get your InVision link.
I love it.
You know what that shows me?
It shows me you care about product.
And in this day and age, you know what wins?
Product.
You know what else wins?
Product.
You know what wins especially?
Product.
You know what doesn't mean?
Talking.
Business plans.
Spreadsheets.
Garbage.
All of it.
Garbage.
Hit delete.
An InVision mock-up will get you the money you need from angel investors.
A business plan will get you shift, exclamation point, spam, shift, pound key.
Delete InVision link.
Click win.
That's all you need to know.
The product is so slick.
The product is so affordable.
InVisionapp.com slash twist.
You have to use this product.
It is so effing awesome.
All right, that's it.
Let's get back to the program.
And cystic fibrosis is a major focus or one of the big wins early on.
A lot of people have given their information so far.
We include cystic fibrosis testing, or we did include cystic fibrosis testing on our health
reports.
We do not have that right now.
We're filing on blooms, which is a rare, inheritable condition in the Jewish population.
And so when you look back on the last nine or 10 years, what is further ahead than what
you thought it would be?
And what is just mind-bogglingly behind?
Or did you even think with a sort of a 10-year arc?
Because it seems to me that you have like your whole entire life arc with this company.
You're going to die doing this, right?
And so—
Hopefully not soon.
Not soon.
But I think I will.
It feels like this is your life's purpose, and you're 10 years into it.
Where did you think you'd be at this milestone, getting close to a decade into it?
The thing that I'm most inspired by is when we go around D.C.,
this idea of consumer health.
And if you listen to—Obama just announced this initiative on precision medicine.
And if you listen to his speech, one of the things that he says is about consumers should
have their data.
And that was a completely foreign concept when we started.
People did not think about consumers owning their information and this idea that consumers
should be engaged, and you should be a partner.
And I was just going through my email before coming on here, and emails from insurance
companies to hospital groups to everyone talking about how it's just this obvious idea now
that you should have your own information.
And before, it was much more—I anticipated that that would be a trend that would take
much longer to accept.
But in some ways, when we go to Democrats, we go to Republicans, we go all over in the
White House.
Everyone resonates with this idea of, I should get my data.
And to be honest, even your ownership of the genetic information and your ability to interpret
it, no one argues with us.
People will say, oh, you need this to be accurate.
But no one argues about that concept that you should have your own information.
And when I ask people, hey, does anyone love the healthcare system?
Anyone love the experience of being sick and going in?
There's really no one who loves it.
So in some ways, we're kind of barking at that tree.
People want the change.
So I'm inspired by the fact that that notion is so broadly accepted on both parties.
The thing that I have been disappointed with, clearly, is I never thought we would have
to stop selling health.
I still wake up in that shock of, I can't believe that actually happened.
Where do you think now projecting forward 10 years from now will be?
Because things do seem to be accelerating now.
And it's kind of hard to know.
But it does feel like there's a little bit of a slope here with computing, artificial
intelligence, and the progress companies like yours are making.
And people like Yuri Milner are taking flyers like this.
We seem like we have a lot of people who want to catalyze this.
I guess people get old, and then they start realizing they're going to die.
And then they're like, yeah, I have a bunch of money.
Please make me live a little longer.
I think it's not as much on the—I think people see a system that's broken.
And I see—it's like anything.
You go to the store, and you're like, oh, you could do it so much better in this way.
And I think people don't really understand the dysfunctionality of health care until
they're in it and understand, what does it mean when you have to fill out the form every
single time you come?
They don't understand what that pain is or the redundancy of having to go from lab to
lab to lab and do the exact same tests over and over again or trying to get your medical
records.
And the fact that an electronic version of your medical record can count as you walk
into a doctor's office with your $25, and they give you a USB stick, and that that is
acceptable.
So I think people don't realize that pain until they actually try to do it.
It's one of the things I always challenge people.
Get your medical records.
If you think that blue button is working or hit all these electronic—then get it.
And it's almost impossible to.
Yeah.
And 10 years from now, if you guys keep up at this pace, it'll become $10 to put somebody
through the system, and maybe you have 100 million people or maybe a billion.
I think that the system's really—so in my mind, this whole system is evolving.
The break in the infrastructure is the consumer empowerment.
Because once the consumers actually have a voice, everything changes.
And I think that consumers don't want to ideally go to the doctor.
If my child has an ear infection, I don't want to go to Kaiser and have them look.
I want to use CellScope and take a picture and send that.
And that's happening more and more.
And I think that that kind of—I'm not sure you have mainstream buildings that you're
going into.
I think the revolution that I see coming is not—which I kind of love—I think the revolution
is not coming from the hospital systems as they are now, but the fact that Walmart is
putting physicians in their stores.
And I go to Walmart three times—or I don't—but you go to Walmart three times a week, the
average American.
So you're going to Walmart at a time.
You buy your food there.
If health is really part of your lifestyle, then you have to make it part of where you
are living your life.
And no one wants to go to their hospital.
Or their doctor's office.
So I think that revolution is totally changing.
And I think that also—again, more companies here, like Grand Rounds and what—you have
an opinion out there.
And I have a friend in my son's school, and he's like, with a mom, she has sarcoma
in her hip.
And she got one opinion.
They did the surgery really quickly.
And it turns out it was a complete mistake to take this out, because if you take out
a sarcoma tumor, then you drag it across and it spreads.
And now it's spread.
It's one of those things—if they'd had 10 opinions, she's like, if I'd had 10
opinions, I would have done things in a completely different way.
And I think that's where that instantaneous—you have an abnormal-looking mole, you just put
it up online.
You get 10 opinions, 15 minutes, $20, bang.
Like, you're done.
And so that model—
And there is a company doing that, that lets you take a picture of moles and like—
Right.
And I think that's where the U.S. is going to fall behind because of this idea of
infrastructure.
When I talk to doctors and they're like, it's so unrealistic to do that because if
I'm a physician in California, I can't practice in Maine.
I can't practice.
So that has to change.
Or you go into India or China or Australia, and you run all of your tests there.
It's one of those things—with your information, I can put the picture of my mole up anywhere,
and it doesn't matter where people are assessing it.
And I think that's where the U.S. will fundamentally fall behind if we're so caught
up in protecting our own little territories.
And it seems like we're living in a time of change right now because we see other issues
in society—marijuana, gay rights, etc.
Everything seems to be switching.
So this has got to switch.
I mean, right?
I think the thing that—
Do you feel hopeful about it?
I'm not hopeful about it changing from within, but I'm hopeful.
And part of the reason why I agreed to come here, it's this kind of community that's
driving the change.
We went out with one of the big insurance companies, and they were saying—she's like,
you don't understand.
All these people, they want to be in healthcare, but being in healthcare is like being a supermodel.
Everyone wants to be like me.
Everyone wants to give me money.
I'm a supermodel.
And there is a little bit of this mentality.
Once you have a system in place in healthcare, and you're just making money, cha-ching,
cha-ching, and you get these contracts, you're like, the government gives me money.
There's so much money in healthcare.
I mean, and I always say, we get all excited about Instagram being bought.
It's like huge money.
And then you're like, healthcare is $2.7 trillion.
It is so much money.
And so the people broadly looking at it are really stuck.
And it's just like an entrenched infrastructure.
So the only things that are going to change, I think—and the reason why we started 23andMe
is because you've got to build it from outside.
Because no one inside the system is incentivized to change.
And you've invested $100 million or so in this company.
What would it cost to do it today, just in terms of what you've built?
Is it much cheaper to do it today?
Or is it similar, do you think?
Because a lot of people, let's face it, in the last 10 years were very scared of even
going into healthcare.
As an entrepreneur, it was sort of like going into music.
You're like, oh, that's going to be just painful when I have to go to the music labels.
It's going to be painful when I have to go to the insurance companies.
Why would you even put yourself through that?
You guys were crazy enough to do that.
In some ways, I love competition, and I hope more competition comes in.
But until there's a regulatory path, it is impossible for someone else to come in.
The regulatory path has to be defined.
For someone to come in and spend the amount of money and have the expertise in doing these
things and putting in a quality system, it's not realistic for a startup to just come and
say, hey, let's do this.
I don't know how much it's going to cost.
Part of it's going to depend on the regulatory system.
The reason why I push and the reason why I go to DC all the time now is I really worry
that they're going to make the whole diagnostics environment a system where you just have a
few big companies and you kill innovation.
The scrappy lab at Stanford or UCSF that makes a discovery, finds something new, they can
test it out, those days will be gone.
Have you guys actually thought about or done scenario planning of, if we do this outside
of the United States, what would it look like?
Are you operating outside the United States?
How is it different?
We have launched in Canada and the UK, and we are giving health reports back in both
of those countries.
We don't have a lab out there.
We don't have offices out there right now.
Fundamentally, I'm a little bit patriarchal in that sense.
We're a US company.
We're going to make the system here work.
There's enough outside pressure on this older school system that the system is going to
change.
Ah, yes.
Citrix GoToMeeting is my go-to way to host a meeting, and meeting is believing.
GoToMeeting, I literally, before I got in the studio today, did a GoToMeeting with my
friend Jeff Duchess, who is launching a new incredible company at the launch festival.
Now, why is that important?
It's important because, A, the meeting needed to start on time because I got a busy schedule
right now.
Two, we had to flip back and forth between him being the presenter, his designer being
the presenter, and me being the presenter.
All, beep, beep, boop, instant, perfect, flawless.
1080p camera, awesome.
Felt like we're in the same room.
And the price, we're talking about a couple of bucks a month, not thousands and tens of
thousands of dollars.
No, just a simple couple of bucks a month, and the meeting starts on time, and there'll
be no delays, and it's flawless, and you're not going to be on somebody's open bandwidth
and have the audio cut out or the video cut out.
It works so well.
And I told him, hey, I'm going to start posting you chats and notes in the chat room because
it has a chat room built into it.
You do your presentation.
I'm going to mute myself, and I'm going to put in notes.
It went so flawlessly because he's getting perfect notes from me on his performance,
and we have perfect audio.
I love this product.
I've been using it for five years, and anybody can join from any computer, tablet, smartphone,
obviously.
And you can turn your webcam on, and you can have HD video conferencing.
I very much recommend the Logitech 1080p camera.
I love that camera.
I buy them by the half dozen.
I literally, this is a true story.
I buy the Plantronics headset, like the DSP-400, and there's a new one, I think it's DSP-420.
I don't want to make it a commercial for Plantronics.
But I buy $30, $40 headsets.
I send them to important people who I meet with often, and I send them the 1080p camera.
And for like $75, the people I meet with have a brand new camera and a perfect headset,
and it feels like we're in the same room.
I mean, even if they use those cheap Apple earbuds, those work too.
But sharing the screen perfectly is one of the best parts of it, and GoToMeeting is as
simple as a click away.
And I also found this other thing that nobody knows about.
In Chrome extension store, there is a little Chrome extension that when you're opening
up a calendar invite, you press one button and it adds your GoToMeeting information and
the link.
So I don't have to go to GoToMeeting and cut and paste it, because that would take me like
seven seconds.
I could just click a button and have it take 0.7 seconds.
Anyway, I'm always trying to be more efficient, and Citrix GoToMeeting makes me efficient.
And you know what?
With all this bad weather going on and people getting on planes or even having to drive
from the valley up to San Francisco, vice versa, out to Berkeley, it's a pain in the
neck.
Nobody has time to waste.
Use Citrix GoToMeeting.
It is awesome.
It is flawless.
And I, Jason Calacanis, personally endorse it.
OK, let's get back to this amazing episode.
And so let's talk about the data for a second, because I think that's also kind of scary
for people.
And since you have Google as an investor and you're a little bit associated with that
company, people are a little bit scared about data.
And you kept talking about the consumers owning their data, and that's really important to
you.
What data do you own?
And what are the data rights, especially to the people who maybe did this at a discounted
price?
And should people be absolutely scared that something's going to happen with their data?
So I think the whole concept of being terrified of data, I think in part comes because
traditionally in research, or actually in a lot of companies even, you sign over the
rights and then they never tell you what happens.
When I was on Wall Street and I would hear about this idea of a human subject, like you
fill out a long consent form and then you sign away your rights and you are a human
subject, it kind of terrifies me.
I want to know what you're doing with it.
I've had some scary experiences with doctors who are like, oh, I took a picture of you
in this way and I used it in a presentation.
And I'm like, what?
You did what?
What did you do?
And so most people don't know what they've signed.
So we're trying to do the exact opposite, where we're trying to say, we will honor your
privacy and privacy being defined as a definition of who do you want to share it with?
It might be that you want to share it with no one.
And it might be that you are an individual with sarcoma and you want all researchers
in the world to have access to it.
And so we want to enable you to control your data.
And so it's really about that control.
So you sign up, 80% of our customers consent for research.
And then once you're in that research pool, you have the additional opportunity of saying,
do you want to take a survey on sexuality?
You don't have to.
Some people might be opposed.
You can, you cannot.
You want to take a survey on Parkinson's.
You want to take a survey on allergies.
So depending on what's of interest to you, you can kind of vote with your feet about
what is it that's of interest.
And then we say, we're going to do partnerships with pharma companies and academics, but in
the aggregate data level.
And so your individual level information is never going out the door, but it's the aggregate
information.
And if we ever are going to do a project with your individual level data, we'll go back
and we'll ask for your explicit consent.
And I'll get an email and I'll check a box.
You'll get an email.
I mean, usually it involves more work.
Like, Hey, can I come and get a punch biopsy from you?
Yeah.
So, so you're, you're quite aware of that, but people, I mean, the consent rates that
we have for individual level data is extraordinarily high.
And I think part of like, you see the goodwill enthusiasm of people who want to go and do
walks and, you know, participate and change the world.
Like if all of you had a friend who's like, Oh, my child has epilepsy.
Will you help me with this?
Like, could you be a part of this?
Everyone's going to do it.
And so that's kind of what we're trying to tap into is like, how do you do that?
And really doing it for good.
Like we have kind of this title, like genetics for good.
Like you can do good things.
And the most important thing for me is like, you should be aware of it.
So when we do contracts with pharma and part in academics, one of the big contention points
we have is we have a requirement that you have to publish an open access journals.
So again, cause like that whole world's never going to change, but like, it's insulting
to me that if I have a consumer population of 850,000 people, and then they have to pay
$25 to read a report about their data, it's kind of insulting.
So, so it should be available.
And so we have a list of all the publications that we have.
And we have, you know, I mean, a lot of consumers, you know, like there's a Time magazine article
today about our paper on motion sickness.
So people can read about that and they know if they've taken that survey.
Tell me about that.
Cause that's like my kryptonite.
I actually have like horrible motion sickness.
Oh, do you?
Well, you could look at, I mean, part of what you can see is you can look online now and
you can look at your raw data.
I don't think we can fix it, but like maybe we can, like that can lead to some kind of
targeted identification.
So you find out like this group of people have it.
And then like if you have, for instance, you have small children, they don't speak, you're
driving down to Big Sur, are they going to vomit or not?
Because you could probably prep your car.
82% or whatever percentage.
You just described my entire childhood.
It's like literally me outside the window.
We will cover you in plastic.
Yeah.
So what's the biggest tangible win that's come out of this in terms of
maybe working towards cures of diseases or management or prevention?
Do you have like ones that you can say like, Hey, wow, this is really like starting to
impact people's lives, either quality of life, extension of life, reduction of pain, or is
it still in this sort of informational kind of understanding who we are mode?
We get stories every day about people where the information has impacted their life.
Like one of my favorite stories is a guy from Seattle who wrote and he had, we'd sent out
a call to all of our customers, send us your stories.
And he said, like, I couldn't have had better timing.
He's like, I just came back from climbing Mount Kilimanjaro.
And a year ago, I was in a hospital.
And I just assumed, you know, looking back a year ago, I just assumed I was one of these
like old 41 year olds that couldn't exercise.
And he'd had nasal problems.
He had breathing problems.
He thought he had post nasal drip.
He'd had a bunch of surgeries.
And he collapsed one day going up the stairs.
And then his sister, I think it was his sister who got 23andMe and saw that she was a carrier
for cystic fibrosis.
And then that prompted him to get tested.
And even though his father's a pulmonologist, he found, he went and he got tested and he
found they actually had sort of a subclinical case of cystic fibrosis.
Holy cow.
And with treatment, he was able to then leave and go hike Mount Kilimanjaro.
So it's one of those feel good stories where you're like, we just completely changed this
guy's life, where like he suddenly like he has the proper treatment and he's able to
really live now.
And I'd say we get a lot of those stories also with the BRCA variants.
So people who find that they're high risk for breast cancer and never would have known
and wouldn't have met traditional screening or reimbursement guidelines because they weren't
of Jewish descent or they didn't have a family history.
And I think those are the stories that there's a clear immediate benefit.
Even one of my other, one of our good friends, her father died of an adverse event when he
had a stroke.
He had a stroke.
They gave him medication and then he suddenly died and they said it was an adverse event.
And then she got her warfarin results and she found that she's one of those people who
has like significantly higher sensitivity to warfarin.
And so I was like, well, it wasn't really an adverse event as much like they overdosed
him and he bled out.
And so it's really useful for her to know.
They killed him.
A little bit.
Yeah.
So, so it's a, I mean, I don't know how to say it.
I tried to soften it, like, hey, it's good that you know that you should be aware in
case you ever had this issue.
You're very sensitive to this medication.
Yeah.
And so I think those have huge impacts from a research angle.
There's, there's a lot of research, the types of research that I'm most excited about doing
I mean, research discoveries take a long time to manifest, but part of like one of
the most interesting studies that we did early on that didn't end up holding up.
But we looked at all of the people who have the Parkinson's, who have Parkinson's disease.
We looked at all of them who are genetically high risk for Parkinson's disease.
And then we looked at the people who are genetically high risk over 70 and don't have
the disease.
And we started to see an association in a gene called SGK1 that looked like it was a
potential modifier.
So we then did a partnership with Scripps to do the follow-up work on it.
It didn't end up holding up, but it was at least like, and you should expect in research,
you will fail all the time.
And in part, like part of the culture we're trying to do is encourage people to fail.
So, so it didn't work, but it's the right kind of study that we want to be doing.
Like we should be looking at your genetically high risk for Alzheimer's, you're 80 years
old and you're sharp as a tack.
Like, what is it that's in you or that what you've done in your life, or what is it that
you have a genetic modifier that has enabled you to be like that?
And I think those are the types of research projects that we're going to be able to do
that are super interesting and that will lead to drugs, you know, therapies or prevention
and more and more.
I mean, it has been a long battle with pharma of getting them to embrace genetics again,
because there was sort of an over a hangover from 99, 2000 when genetics was seen as like
going to be the panacea for all drug discovery.
And, and now there's, they're starting to really see the potential.
And so I think we're going to start to see more and more discoveries that are coming
from a genetic basis.
So, um, big data is here.
It's like actually impacting a lot of businesses.
People are doing all kinds of auto magical stuff on Netflix or Pandora to tell you what
you like.
And if you could take another data set and correlate it to the million people that you
have or so, like say a blood test, or I'm not sure what, or everybody wears a wearable
for a hundred days and you had a complete data set of a hundred days and I don't know,
a blood test.
What would you be able to tell us, or what would the research be able to tell us?
And has anybody done anything remotely close to matching those kinds of data sets?
The activity that, yeah, thank you.
Yeah.
Like you said.
Yeah, it's, um, I mean, we, we debate this quite, quite a bit, um, in part because also
there's so much data that's coming in and what's the right data.
In some ways you kind of want all of it, um, you know, blood data, I would say to start
with blood data is probably the most valuable because you want to potentially be able to
correlate trends in your, in your standard lab values with potentially an early diagnosis
for something.
Um, you know, the activity data, you don't necessarily need all of the data that is coming,
but you potentially need certain kinds of data points or the deltas, the changes that
are happening.
Um, there's all kinds of things that are going to be interesting that people don't realize.
So for instance, we had a talk yesterday in the office about Parkinson's disease and,
um, people who have REM sleep disorders or like who have problems sleeping, um, it's,
it's a predictor for Parkinson's and sort of uniform, like these people end up having
a problem.
And apparently the sleep doctors always knew this, but it never translated over to the
neurologist.
And, and there's things like that.
And people with Parkinson's as well, they start to lose their sense of smell.
So there's things that are going to be really interesting to be able to detect.
Um, what I think about always from our research angle is what is it that the consumers want?
And ideally, like we're all in the room, everyone's relatively young in here.
Um, you want to know how to prevent disease.
And so there's two things to me that are interesting in prevention is one is the things
that you do day in and day out as you eat and you breathe your environment.
And so I'm super interested in what is it that you're eating and how does it actually
potentially really influence and any kind of environmental exposures.
So like environmental working group does a bunch of interesting studies on like, like
what truly is the harm of Teflon in your food.
And, you know, like I would love to do, like I did a body burden study, uh, eight years
ago where I was really high in fire, fire retardants.
And it was a thing, fire retardants, fire retardants.
And they joke, they're like, oh, you must fly a lot and coach.
And I said, yes, because I was from the wall street days.
Like you fly all the time.
Like that's, if you think about airplanes are covered in fire retardants and you're
breathing circulated air, so you're absorbing a lot of fire retardants.
Um, so I think that there's, it just kind of interesting to study those components because
what the consumer ultimately is going to want is like, you want to stay healthy.
And if I can give you that guide for staying healthy, um, so it's a little bit of a long
answer.
I mean, I do think that the blood data and, and medical records are going to be sort of
first priority list for us.
Um, but then figuring out a way that you can really track environment and, you know, GPS
from your phones that matches with pollution statistics from the country and sort of your
gross, you know, how much are you actually exercising every day on a relative basis to
peers like that information is going to be super valuable.
And for us, so it would seem to me, um, you did this great thing by lowering the cost.
Thanks Yuri Milner.
Um, and Facebook or wherever he made the money.
I mean, a ton of money off that, I guess.
Um, can we ask him for like another hundred million dollars to just do it like for the
blood test then, and then put them all together or what, why wouldn't you offer, there is
this high end, right?
Of people in the market, let's say the top 10% who will pay like any amount of money
to live longer or live better.
Could you offer like a 360 degree package for a hundred dollars a month, let's say where
people took a regular blood test?
Warren activity tracker that then correlated.
And maybe you could build up a subset of 10,000 people in the world who are paying you a hundred
dollars a month, which I think is a couple million bucks.
And then you'd have that group as like this incredible base of data.
Have you guys thought about doing something like that?
We've, I think the promise 10,000 is too small.
Like we're a little bit at that data greedy point.
Like you want scale, like I want, um, I want whole, I have 850,000 people in 23 Muse community
and they're all biobanks.
Most of them are biobanks.
So like one, we could just sequence all 850,000 people at some point.
Um, and if blue button worked one day or people could actually get their medical records,
I don't need to pay for you to go and get a blood test.
Like I just get it.
Um, it's a data normalizer too though, right?
If the way you'd have to like normalize all this data from all these different labs, that
would be a lot of work.
I'm just thinking if you gave me a package where like, where there was a, you're going
to have to normalize it anyways.
Cause you're not good.
I mean, that's part of where like the beauty of fairness really takes off in this way.
And you could get, if I could do a blood spot every month and send it off, that would be
also awesome.
I mean, in some ways you're going to want continuous blood monitoring at some point,
but that's not in our, that's not your term.
Um, but I think it's fine.
Like it's a starting point.
Like it's, it's better.
It would be better.
I would rather have data on all, if I could get medical records and lab values on all
in a scalable way versus 10,000 people really closely.
Like I had to go for the 850,000.
Yeah.
And so, and part of what I think about too, like we're selling a lot still.
It's one thing people don't like people thought we got shut down.
Like we're selling a lot and we have a lot of customers.
Like we're growing all the time.
So, so any, like everything I think about though is, is based on that scale.
Like I'm super interested in the scalable ways of getting medical records.
So these deals that you're doing with the pharma companies, those are
millions, tens of millions of dollars in value.
Um, what, what's the scale of those?
They have, um, there's in all of those, there's sort of an upfront, I mean,
they're getting bigger and bigger with each project that we're doing.
There'll be upfront fees and then there's milestones on them.
Um, so part of it is that we have more ability to say, we want to get part of what comes
downstream.
So if there's going to be a therapy that's developed or there's going to be some,
something that's developed or IP that's filed, we want to get part of that.
So you can get a licensing for your royalty or something, something there.
Uh, that could be significant, huh?
It's interesting.
I mean, we have, um, since day one, people have like Art Levinson at Genentech.
He was one of our first investors and he's like from day one, like what's really like,
you will transform drug discovery and how do you, how do you get part of that?
So if from our, from the beginning, we've often thought like, how is it that we get
into, you know, I, if, if you have a group of consumers who have sarcoma and what they
really want is a therapy for that, the best thing that we can do is help move that into
really making it a therapy.
And part of the bottleneck that we're getting a little bit now is like, you know, convincing
pharma to change is, is hard.
Uh, so they have to pay an upfront fee and then agree to some sort of backend.
If you just went to the mall and said like, Hey, the data's free, but the backend's a
choice.
Like, Hey, some cash, some backend, or can you just say like to all of them, like, or
just go crazy in there and just give us like a much richer backend.
I think that business model would be hard to sustain for them because you don't, it's
10 years out.
Yeah.
If there was an infinite supply of cash or like something that could be great, but that
would be expensive to manage.
So how close is the company to being like a sustainable concern?
And was it going to just need to be sort of invested in for another decade or?
We were quite close pre FDA letter.
We were quite close.
We were really on that brink.
Um, makes it even more tragic, huh?
It does.
I know.
Like I said, I wake up all the time and think what happened?
Um, but it's, you know, but part of it is like, like we have, we have a long-term vision
and one of the things that happened actually after that FDA letters, we went to go see
different people in regulatory and they're like, look like this is probably going to
be a really net positive thing for you.
And, um, and if you have that 10 year horizon and you build towards that, this is going
to be incredible product and opportunity.
Like what we have done here is like defining a direct to consumer channel that will have
an FDA clearance.
And I think there's a massive potential for that, of being able to say, we've worked
with the established system and we're enabling a direct to consumer.
Like this will be a huge event to be able to say more and more things are going to be
able to be, you know, without a physician and challenging this notion that is a physician
experience actually the appropriate gold standard, right?
Um, it might be like you're saying earlier, 10 physicians reviewing something might be
the gold standard, but doing it remotely and getting some consensus around, uh, having
video communication, like watching a video about, like I think about when I did my amnia,
would I rather have spent the time with the woman in the flip book or would I rather have
watched a video?
I probably would rather watch the video.
Um, so the point where it's like, there's, there's potentially something that's more
scalable by having videos and standardized content versus like the, the variability that
comes with the one-to-one interaction.
And is it really so valuable to have that one-to-one interaction and say, okay, here's
your genetic information.
Like I've seen multiple times.
I used to work at San Francisco general multiple times in the emergency room where the doctor
will scream over.
Oh, your father has like colorectal cancer.
That's why it's like, he's having these problems.
You should go see oncology.
And you're like, oh, that's how you delight.
Yeah.
That's how you said that he had cancer.
So like, like that, that experience is like, there's a huge variability and is that potentially
a better experience that we can have like by defining direct to consumer and potentially
saying you can have information sources that are just, are just as capable of communicating
to the consumer as having a really highly qualified individual communicate that and
potentially having, I mean, the reality is like you're, we don't have enough genetic
counselors in this country.
There's not enough physicians to give sort of the, the, the highest quality care.
So how can you actually really scale that, that care in a, in, in a much more cost-effective
manner?
Yeah.
So some questions from the audience.
I'm sure people have questions.
And so do we have a microphone that gets picked up?
We do?
Okay, great.
And I think we had one right here to start.
And if you could say your name and maybe your company name and then a really concise question.
My name is Denise Terry.
I'm with Embrace Her.
We do women's reproductive health.
So I've been a 23andMe customer for about four years.
I had my twins tested right after they could spit in a vial.
And I was really angry when the FDA shut you down because I was about to have my parents
tested for the full family history.
We're also a partner.
We were a partner.
And you were marketing with us to reach women, right?
Because women have a lot of reason to test their family.
So my question is, how, how soon do you anticipate getting permission to market yourself again
with, you know, the way you used to with the full genetic information, giving people access
to their data?
My parents actually got tested, but we got all the gobbledygook of information.
They can't decipher it.
So what's going to change and how soon?
Yeah, I mean, that's where I would love to know.
We've submitted on one report.
And the challenge there is like, it's one report.
We had 250.
So even once we get a clearance for that one report, we still have to then figure out that
path.
The one thing that is happening is there is a real desire for the FDA to figure this out
because sequencing is getting cheap.
There's all kinds of sequencing products that are coming out there.
So it's a problem that has to be resolved.
And I think there's also this recognition, you know, that, you know, this is a, it's
so like, it's not a scalable for all these companies to start to do something like this.
So, I mean, I still think it's going to take some time.
But I am hopeful, you know, I'm hopeful that we'll see progress, significant progress this
year.
But I still think it's going to take some time to work out.
There's a next generation sequencing workshop that's happening, I think, February 19th,
20th.
And if you read that guideline, the white paper that came out with next generation sequencing
is really interesting because it talks more about a scalable model for approvals.
And so if that happened, that would actually be quite interesting.
But overwhelmingly, I mean, we hear, it's like the number one complaint that we hear
is people who have the experience, they're like, I want to get it for others.
And...
Yeah, you get a PO box in Canada, you could actually hack it.
So...
Oh, yeah.
Hi, I'm Michael Ball with Genealogix.
I'm curious as to whether or not you see yourself offering whole genome sequencing in the future.
I've had my whole genome sequenced.
It was very time consuming, lots of, you know, I'd much rather have a direct to consumer
option.
I'm just wondering at $1,000 per whole genome, how soon are you going to offer that?
Yeah, what would that cost too?
Yeah, we have...
The one thing that we learned in the early days, like when we first launched,
and there was a little bit of this turf war of like, who's offering more SNPs,
like we were 550,000, the competition of like a million, like,
and we really quickly learned no one cares.
It was kind of like an ego war between ourselves.
The whole genome is super interesting for, you know, super interesting potentially for you,
if you're going to try to explore it and understand it.
It's only interesting for the customer if I can tell them something more.
And so I've stuck really hard to the genotyping, because it's cheap, it's highly reliable,
and I can tell you a lot of meaningful information about yourself.
So you can definitely get more from whole genome.
But to your point, there's a lot in there.
And it's kind of unwieldy.
And you don't, like, what are you going to do with everything else?
There's definitely things I can tell you with a whole genome,
but I can't tell you with our chip.
And we are exploring that 100%.
But everything, again, our filter is all about what is it that's meaningful that I can tell you,
rather than just like saying I'm giving your whole genome for the sake of the whole genome.
Because what we've learned, like people don't care.
So question about, as we're wrapping up here,
the actual technical, tactical giving of the advice and the interpretation of, you know, the kit.
What if there was a third party that was an open source or,
you know, nonprofit or something that actually contained that?
And I could get my report, and it would say, you know, you can go to the Wikipedia of this and,
you know, type in this, and you could see what they have to say.
And they're based in Switzerland.
What we have is, we actually have an open API.
And so Mike Pocari, who's sitting right there, he runs it.
And Brad Kittredge, who's around here, who runs product.
That's kind of the team.
Like we have, the whole philosophy was that you get your genotype,
and you get your information.
We're going to interpret, you know, to our standards.
But there's going to be other people who want to do other things.
And it might be that there's somebody who wants to tell you about,
you know, different shampoos that you're more likely to respond to,
we're just not going to necessarily do that research.
So we have 1,200 developers looking at it now.
We have 60 approved partners that are leveraging the API.
Everyone's from someone like Prometheus, which is probably better known in this crowd,
to, you know, you know, different, like Harvard actually was using it for a while.
So I would love to encourage, and that's actually something that we've thought about doing,
is I think when I look at the startup community,
one of the things that's hard is a lot of you just don't know the basics about genetics,
and how do you integrate into your product.
Like greeting cards.
There's probably really interesting things you could do from grandparents to grandchildren
in terms of how genetics are being moved down.
And you could do really cool cards.
But like people in greeting cards don't know a lot about, you know, DNA.
And so how is that we can teach people?
And it's part of what we've thought about doing is like,
should we actually have programs to really get people using the API?
Yeah, you should definitely do a hackathon with prizes.
Yeah.
And then Hallmark's data science team will show up, and they'll just do a great hack.
Well, we've talked about doing some hackathon, like things like that,
but I think that's part of where we're thinking more and more is that we are,
we want you to use your DNA.
Like we've been antithetical as well with this idea that you should own your information,
and you should do things with it, and like take the ownership, and you know,
move it around, and like enable other people to do stuff.
So if we can create that ecosystem of like, you all have companies,
and if there's a genetics angle, well, then you can leverage our API.
It would be just like authenticating with Facebook Connect.
You'd be like, 23andMe, boom.
And it's like, would you like to give them the ability to post on your wall,
or pull your genetics?
Yes.
All right.
So we're close.
Hey, let's hear it for Anwar Jaki.
